HEИндивидуална стипендия2022–2024

B-ALLeles · High resolution dissection of non-coding determinants of disease

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период: 2022-11-01 → 2024-10-31
Финансиране от ЕС: 183 601 €
Участници: 2
Схема: HORIZON-TMA-MSCA-PF-EF

Линиите свързват координатора с партньорите.

Накратко на български

Генетичните вариации в некодиращите части на ДНК се анализират, за да се разбере как те влияят върху развитието на детска остра лимфобластна левкемия. Това помага да се установи как се регулират гените и как се задейства това заболяване.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

High resolution dissection of non-coding determinants of disease

While mutations at protein-coding sequences have been extensively characterized, the functional role of disease-associated non-coding variants remains largely elusive. In fact, germline non-coding variants are often associated with increased risk of childhood cancers, especially in the case of B cell acute lymphoblastic leukemia (B-ALL). Furthermore, non-coding variants have been shown to affect transcription factor (TF) binding, therefore altering the activity of gene regulatory elements and the expression of their associated gene. In B-ALL, while some risk-variants are associated with B cell lineage-specific genes, others are associated with genes with uncharacterized function. Thus, in this project, we hypothesize that non-coding variants associated with B-ALL affect the activity of distal regulatory elements, modulating the expression of their target genes and other B-cell lineage-specific genes (objective 1). We further postulate that risk-associated genes with uncharacterized function regulate lineage-specific genes (objective 2), playing a crucial role in B-cell development and B-ALL initiation and progression (objective 3). To test these hypotheses, I have knocked-out risk-variant containing regions (towards objective 1), characterized the molecular mechanism of a risk-associated genes using genomics and proteomics (towards objective 2) and am currently studying the physiological relevance of the associated genes and its interaction partners in B cell development in the mouse (towards objective 3).

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

While mutations at protein-coding sequences have been extensively characterized, the functional role of disease-associated non-coding variants remains largely elusive. In fact, germline non-coding variants are often associated with increased risk of childhood cancers. In B-cell derived acute lymphoblastic leukemia (B-ALL), the most common type of cancer in children, non-coding sequence variation at lineage-specific genes, such as IKZF1, GATA3 and CEBPE is associated with disease. Interestingly, the strongest risk factor maps at ARID5B, a DNA-binding protein described to promote the removal of repressive histone marks. Still, the role of ARID5B in leukemia and haematopoiesis remains largely uncharacterized. Thus, we hypothesize that non-coding variants associated with B-ALL affect the activity of distal regulatory elements, modulating the expression of ARID5B and other B-cell lineage-specific genes (objective 1). We further postulate that ARID5B promotes the de-repression of lineage-specific genes (objective 2), playing a crucial role in B-cell development and B-ALL initiation and progression (objective 3). To test these hypotheses, I will develop a novel CRISPR screen approach to dissect ARID5B enhancers at single nucleotide resolution (work package 1). I will use a combination of genomics and transcriptomics methods after acute and prolonged degradation of ARID5B to elucidate the molecular function of ARID5B in B-ALL (work package 2). Finally, I will use mouse models and focus on the physiological relevance of ARID5B in B-cell development and leukemia initiation and progression, in vivo. (work package 3). Together, I will dissect the role of non-coding variants at leukemia-associated loci, characterize the molecular function of ARID5B and elucidate the pathophysiological relevance of ARID5B.

Оригинален текст от CORDIS (на английски).

Участници

ST. ANNA KINDERKREBSFORSCHUNG GMBH · WienКоординаторАвстрия
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH · WienАвстрия